Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































Supreme Court Decision Removes Barrier to Importing US Patented Drug Products at Lower Cost
/in Policy Blogs Legal Resources, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersIn its May 30, 2017 decision Impression Products, Inc. v Lexmark International Inc., the Supreme Court ruled that patent law cannot be used to prevent the resale of products back into the United States. The Court case specifically concerned printer toner cartridges, but it is an important ruling in the context of the domestic policy […]
Drug Pricing: In the News
/in Policy Administrative Actions, Legal Resources, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffAs States Wage Battles on High Drug Prices, Drugmakers Fight Back May 18, 2017 Lembo targets ‘skyrocketing’ drug prices January 24, 2017 How can states tackle rising medication prices? January 11, 2017 Interfaith investor coalition pushes shareholder resolutions on drug prices, October 24, 2016 Politico Pulse mentioned the findings of the Pharmacy Costs Work Group, October 24, 2016 […]
State Wholesale Importation Program Explained
/in Policy Reports Administrative Actions, Legal Resources, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffBecause the federal government has not been able to agree on an approach to constrain prescription drug prices, states need to address the problem. Study after study show how US consumers pay the highest prices in the world for life-saving and life-enhancing drug treatments. The prices we pay may fund the research and development that […]
Managing High Drug Prices through Importation: We Can Get to “YES”
/in Policy Blogs Administrative Actions, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Lesa Rair and Jerin PhilipThere is growing public pressure to find an effective way to address the rising prices of prescription drugs. Multiple drug price bills await action in Congress and more than 80 bills have been introduced in state legislatures in 2017. Among the variety of approaches aimed at managing drug prices, importation from other countries is an […]
Update: What’s New in State Drug Pricing Legislation?
/in Policy Maryland, Montana, New Mexico, New York, Utah Blogs Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffWith 80 bills introduced in 2017, there is a high level of interest in pharmaceutical pricing among state legislators. However, despite legislative sessions wrapping up, very few laws have been enacted. To date, bills have passed in Maryland, Montana, New Mexico, New York, and Utah. In 2016, Vermont led the way with a price transparency […]
Pharmacy Costs Work Group – Model Legislation
/in Policy Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersNASHP, with guidance from our Pharmacy Costs Work Group, has developed model legislation for states that wish to pursue the policy options outlined in our paper States and the Rising Costs of Pharmaceuticals: A Call to Action. States interested in this model legislation will have access to a legislator’s guide and additional background materials as […]
Pharmacy Costs Workgroup: Model Drug Price Transparency Legislation
/in Policy Administrative Actions, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP Pharmacy Costs Work GroupPharmaceutical prices are rising, driving up premiums and out of pocket costs. State budgets – that by law, have to be balanced– are reeling from high and unpredictable pharmaceutical price increases for Corrections, state employees and retirees, K-12 and public university employees, and, of course, Medicaid. To address rapidly rising prescription drug prices, purchasers and policy […]
NASHP Releases Model Rx Transparency Legislation
/in Policy Blogs Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersPharmaceutical prices are rising, driving up premiums and out-of-pocket costs. Today, 21 percent of spending in employer-sponsored plans goes to retail prescription drugs.[i] State budgets – which by law must be balanced- are reeling from high and unpredictable pharmaceutical increases for corrections, state employees and retirees, K-12 and public university employees, and, of course, Medicaid. […]
Empowering and Protecting Consumers: ERISA Thwarts State Innovation
/in Policy Reports Health Coverage and Access, Health System Costs, Hospital/Health System Oversight, Prescription Drug Pricing, State Insurance Marketplaces, State Rx Legislative Action /by Trish Riley and Erin Fuse Brown, JD, MPHAs the national debate over the ACA continues, this publication looks at why Congress needs to amend the Employee Retirement Income Security Act (ERISA) to assure consumers and payers have the information they need to make health purchasing decisions. The considerable discussion of increasing consumer engagement, in part by expanding the use of health savings accounts […]
High Risk Pools Deja Vu – Lessons from States, Questions for Policymakers
/in Policy Minnesota, Virginia Blogs Cost, Payment, and Delivery Reform, Essential Health Benefits, Health Coverage and Access, Health System Costs, Prescription Drug Pricing, State Insurance Marketplaces /by Anita CardwellCongress has begun its Affordable Care Act (ACA) repeal effort and evolving replacement options are receiving considerable attention. NASHP is tracking issues that appear in multiple proposals and will provide state perspectives, including: How might they impact states? What might they cost? Have they been tried before in states and what did we learn from […]